Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours
2010
BACKGROUND: The role of chemotherapy for neuroendocrine tumours remains controversial and there is no standard regimen.METHODS: We report the outcome for a consecutive series of chemonaive patients with metastatic or locally advanced neuroendocrine tumours treated with a combination of 5-fluorouracil (500 mgm(-2)), cisplatin (70 mgm(-2)) and streptozocin (1000 mgm(-2)) (FCiSt) administered three weekly for up to six cycles. Patients were assessed for radiological response, toxicity and survival.RESULTS: In the 79 patients assessable for response, treatment with FCiSt was associated with an overall response rate of 33% (38% for pancreatic primary sites and 25% for non-pancreatic primary sites). Stable disease occurred in a further 51%, with progression in 16%. The median time to progression was 9.1 months and median overall survival was 31.5 months. The most common grade 3-4 toxicity was neutropaenia (28% patients) but grade 3-4 infection was rare (7%). The most frequent non-haematological grade 3-4 toxicity was nausea and vomiting (17%). Prognostic factors included Ki-67, mitotic index, grade and chromogranin A, whereas response to chemotherapy was predicted by mitotic index, grade and a-fetoprotein.CONCLUSION: FCiSt is an effective regimen for neuroendocrine tumours with an acceptable toxicity profile. Grade and mitotic index are the best predictors of response. British Journal of Cancer (2010) 102, 1106-1112. doi:10.1038/sj.bjc.6605618 www.bjcancer.com Published online 16 March 2010 (C) 2010 Cancer Research UK
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
23
References
148
Citations
NaN
KQI